BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
BridgeBio Oncology Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.85+0.03 (+1.06%)
Close on Oct 19, 2026
- Market cap
- $228.15M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
73.8%
59M of 80M shares
Institutional holders
66
17 new, 18 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sculptor Capital Management, Inc. | 967,460 | 5.12% | 13G (passive) | Jul 17, 2025 |
| James E. Flynn | 4,885,446 | 6.17% | 13G (passive) | Aug 11, 2025 |
| Tan Kuangming | 4,365,747 | 5.50% | 13G (passive) | Sep 4, 2025 |
| Bihua Chen | 17,878,594 | 22.32% | 13D (active) amendment | Jul 1, 2026 |
| BlackRock Portfolio Management LLC | 1,498,865 | 7.90% | 13G (passive) | Mar 31, 2025 |
| Adage Capital Partners GP, L.L.C. | 1,400,000 | 7.40% | 13G (passive) | Feb 13, 2024 |
| BridgeBio Pharma, Inc. | 13,878,554 | 17.50% | 13D (active) | Aug 11, 2025 |
| T. Rowe Price Associates, Inc. | 1,127,598 | 6.00% | 13G (passive) | Nov 14, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BBOT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 17,878,594 | 22.30% | $136.23M | – | 6.98% |
| Deerfield Management Company, L.P. (Series C) | 4,885,446 | 6.09% | $37.23M | – | 0.39% |
| Omega Fund Management, LLC | 3,289,661 | 4.10% | $25.07M | – | 13.50% |
| Alphabet Inc. | 2,823,126 | 3.52% | $21.51M | – | 0.02% |
| EcoR1 Capital, LLC | 2,823,126 | 3.52% | $21.51M | – | 1.05% |
| Wellington Management Group Llp | 2,789,302 | 3.48% | $21.25M | −29,046 | 0.00% |
| Enavate Sciences Gp, LLC | 2,626,946 | 3.28% | $20.02M | – | 5.80% |
| Citadel Advisors LLC | 2,617,827 | 3.27% | $19.95M | +89,065 | 0.00% |
| Novo Holdings A/S | 2,250,000 | 2.81% | $17.15M | +64,077 | 1.00% |
| BlackRock, Inc. | 2,154,040 | 2.69% | $16.41M | +65,743 | 0.00% |
| Vanguard Capital Management LLC | 2,005,649 | 2.50% | $15.28M | +1,467,208 | 0.00% |
| Laurion Capital Management LP | 2,002,701 | 2.50% | $15.26M | +80,045 | 0.39% |
| Armistice Capital, LLC | 1,764,000 | 2.20% | $13.44M | +436,000 | 0.16% |
| State Street Corp | 1,036,569 | 1.29% | $7.90M | +810,291 | 0.00% |
| Aisling Capital Management LP | 1,018,018 | 1.27% | $7.76M | – | 1.64% |
| Opaleye Management Inc. | 700,000 | 0.87% | $5.33M | +646,718 | 0.48% |
| Geode Capital Management, LLC | 622,351 | 0.78% | $4.74M | +43,117 | 0.00% |
| Granahan Investment Management, LLC | 558,526 | 0.70% | $4.26M | +327,486 | 0.15% |
| Sphera Funds Management Ltd. | 460,985 | 0.57% | $3.51M | New | 0.46% |
| Adage Capital Partners Gp, L.L.C. | 400,000 | 0.50% | $3.05M | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 66 | 59M | 73.8% | 17 / 21 | 15 / 18 | 6M | 4M |
| Q1 2026 | 67 | 57M | 71.7% | 23 / 20 | 11 / 7 | 5M | 5M |
| Q4 2025 | 53 | 58M | 72.7% | 15 / 12 | 12 / 4 | 3M | 1M |
| Q3 2025 | 42 | 57M | 70.9% | 42 / 0 | 0 / 0 | 57M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BBOT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,422,900 | 1.77% | $10.84M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 813,301 | 1.01% | $6.20M | 0.06% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 673,766 | 0.84% | $6.04M | 0.10% | May 29, 2026 |
| Vanguard Extended Market Index Fund | 539,581 | 0.67% | $4.11M | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 306,024 | 0.38% | $2.33M | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 250,892 | 0.31% | $2.25M | 0.01% | May 31, 2026 |
| Select Biotechnology Portfolio | 240,300 | 0.30% | $2.16M | 0.04% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 227,258 | 0.28% | $2.04M | 0.01% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 222,512 | 0.28% | $1.70M | 0.01% | Jun 30, 2026 |
| Victory Small Cap Stock Fund | 134,743 | 0.17% | $1.09M | 0.11% | Jul 31, 2026 |
| Tema Oncology ETF | 93,339 | 0.12% | $837.25K | 0.48% | May 31, 2026 |
| Fidelity Total Market Index Fund | 90,376 | 0.11% | $810.67K | 0.00% | May 31, 2026 |
| Royce Micro-Cap Fund | 87,617 | 0.11% | $667.64K | 0.16% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 72,932 | 0.09% | $654.20K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 49,459 | 0.06% | $443.65K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pedro Beltran | President and CEO, Director | 44,576 | 0.06% | Jul 6, 2026 |
| Eli M. Wallace | Chief Executive Officer, Director | – | – | Jan 5, 2026 |
| Marc Cobo | Principal Accounting Officer | 14,141 | 0.02% | Sep 14, 2026 |
| Idan Elmelech | COO & Principal Financial Ofcr | 14,495 | 0.02% | Jul 6, 2026 |
| Yong Ben | Chief Med & Dev Officer | 44,576 | 0.06% | Jul 6, 2026 |
| Caleb Tripp | Chief Financial Officer | – | – | Aug 11, 2025 |
| Nebojsa Obradovic | Chief Legal Officer | – | – | Aug 11, 2025 |
| Bihua Chen | Director, 10% owner | 18,782,194 | 23.43% | Jul 6, 2026 |
| Praveen P. Tipirneni | Director | – | – | Jun 18, 2026 |
| Neil Kumar | Director | – | – | Jun 18, 2026 |
| Peter F. Lebowitz | Director | – | – | Jun 18, 2026 |
| Frank McCormick | Director | – | – | Jun 18, 2026 |
| Jake Bauer | Director | – | – | Jun 18, 2026 |
| Raymond J. Kelleher | Director | – | – | Jun 18, 2026 |
| Michelle Doig | Director | – | – | Aug 18, 2025 |
| Holdings II LLC Helix | Director, 10% owner | 4,989,000 | 6.22% | Feb 10, 2025 |
| Uneek Mehra | – | 22,806 | 0.03% | May 5, 2026 |
| Pharma LLC BridgeBio | 10% owner | 13,805,126 | 17.22% | Oct 16, 2025 |
| BridgeBio Pharma, Inc. | 10% owner | 14,589,846 | 18.20% | Oct 16, 2025 |
| Albert A. Holman III | – | 30,000 | 0.04% | Aug 11, 2025 |
| Mark C. McKenna | – | 30,000 | 0.04% | Aug 11, 2025 |
| John P. Schmid | – | 30,000 | 0.04% | Aug 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marc Cobo Principal Accounting Officer | Sep 10, 2026 | Tax withholding | −203 | $5.52 | $1.12K | 14,141 |
| Marc Cobo Principal Accounting Officer | Sep 10, 2026 | Award | +9,038 | – | – | 14,344 |
| Marc Cobo Principal Accounting Officer | Jul 1, 2026 | Tax withholding | −125 | $7.80 | $975 | 5,306 |
| Yong Ben Chief Med & Dev Officer | Jul 1, 2026 | Tax withholding | −1,047 | $7.80 | $8.17K | 44,576 |
| Bihua Chen Director, 10% owner | Jul 1, 2026 | Other | −4,528,186 | – | – | 0 |
| Bihua Chen Director, 10% owner | Jul 1, 2026 | Other | +2,692,459 | – | – | 4,879,995 |
| Bihua Chen Director, 10% owner | Jul 1, 2026 | Other | +1,704,862 | – | – | 5,010,332 |
| Bihua Chen Director, 10% owner | Jul 1, 2026 | Other | +130,865 | – | – | 6,083,221 |
| Idan Elmelech COO & Principal Financial Ofcr | Jul 1, 2026 | Tax withholding | −343 | $7.80 | $2.68K | 14,495 |
| Pedro Beltran President and CEO, Director | Jul 1, 2026 | Tax withholding | −1,047 | $7.80 | $8.17K | 44,576 |
| Yong Ben Chief Med & Dev Officer | Apr 1, 2026 | Tax withholding | −1,047 | $9.03 | $9.45K | 45,623 |
| Uneek Mehra – | Apr 1, 2026 | Tax withholding | −524 | $9.03 | $4.73K | 22,806 |
| Pedro Beltran President and CEO, Director | Apr 1, 2026 | Tax withholding | −1,047 | $9.03 | $9.45K | 45,623 |
| Yong Ben Chief Med & Dev Officer | Mar 10, 2026 | Award | +46,670 | – | – | 46,670 |
| Uneek Mehra Chief Financial Officer | Mar 10, 2026 | Award | +23,330 | – | – | 23,330 |
| Pedro Beltran Chief Scientific Officer | Mar 10, 2026 | Award | +46,670 | – | – | 46,670 |
| BridgeBio Pharma, Inc. 10% owner | Oct 10, 2025 | Other | +784,720 | – | – | 14,589,846 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +639,110 | $10.72 | $6.85M | 1,542,710 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +5,598,425 | $10.72 | $60.02M | 5,667,785 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +1,905,046 | – | – | 1,905,046 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +1,762,760 | – | – | 3,305,470 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +284,571 | – | – | 5,952,356 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +760,496 | $10.72 | $8.15M | 2,187,536 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Option exercise | +4,172,126 | – | – | 4,681,126 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Returned to company | −152,940 | – | – | 4,528,186 |
| Mark C. McKenna – | Aug 11, 2025 | Option exercise | +30,000 | – | – | 30,000 |
| Albert A. Holman III – | Aug 11, 2025 | Option exercise | +30,000 | – | – | 30,000 |
| John P. Schmid – | Aug 11, 2025 | Option exercise | +30,000 | – | – | 30,000 |
| Bihua Chen CEO and Chairperson, Director, 10% owner | Feb 13, 2024 | Buy | +903,600 | $10.00 | $9.04M | 903,600 |
| Bihua Chen CEO and Chairperson, Director, 10% owner | Feb 13, 2024 | Buy | +1,427,040 | $10.00 | $14.27M | 1,427,040 |
| Bihua Chen CEO and Chairperson, Director, 10% owner | Feb 13, 2024 | Buy | +69,360 | $10.00 | $693.60K | 69,360 |
| Bihua Chen CEO and Chairperson, Director, 10% owner | Feb 13, 2024 | Award | +509,000 | $10.00 | $5.09M | 509,000 |
| Holdings II LLC Helix Director, 10% owner | Feb 13, 2024 | Award | +509,000 | $10.00 | $5.09M | 509,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.